FDA Declines to Approve Akcea/Ionis Genetic Disease Drug FDA Declines to Approve Akcea/Ionis Genetic Disease Drug

The U.S. Food and Drug Administration on Monday declined to approve a drug from Akcea Therapeutics Inc and Ionis Pharmaceuticals that aims to treat familial chylomicronemia syndrome, a rare genetic disorder that could cause potentially fatal pancreatitis.Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Family Medicine/Primary Care News Source Type: news